Toronto, Ontario–(Newsfile Corp. – May 2, 2024) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce today the appointment of Zalman Goldman to the board of directors, subject to approval of the Canadian Securities Exchange.
https://9bae9f8f03f41196df925977bbdaecd5.safeframe.googlesyndication.com/safeframe/1-0-40/html/container.html
Zalman Goldman is the founding Director of Jacs Toronto has spent 20 plus years in the world of addiction and recovery and has used that time to try and make the city of Toronto a safer place when it comes to drug use and abuse. He has sat on the mayor’s council on drug abuse and created dozens of programs over the years to assist families with the effects of addiction. Zalman is a pioneer in the recovery world, and he’s thrilled to join the board of Pharmadrug and glad that it continues to make advancements in the health field, “I’m glad Pharmadrug has a role in making the world a safer place.”
In connection with Mr. Goldman’s appointment, the Company also announces that Mr. Nickolai Vassev has resigned as a director, effective April 30, 2024. The board of directors would like to thank Mr. Vassev for his contributions to the Company.
In connection with his appointment to the board, Mr. Goldman has been granted 500,000 stock options exercisable at C$0.05 per share for a period of 5 years, subject to the policies of the Canadian Securities Exchange and the Company’s stock option plan.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs. PharmaDrug owns 51% of Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. PharmaDrug also owns 100% of SecureDose Synthetics Inc. (“SecureDose”), a pharmaceutical research and development company focused on the development of synthetic formulations of currently existing drugs for potential commercialization and distribution.